Are peptides legal? BPC-157, TB-500 and the July 2026 FDA panel vote
Some are and some are not. A peptide is legal to sell in the United States when it is an FDA-approved drug, or when a state-licensed pharmacy compounds it, on a prescription for a named patient, from an ingredient federal law lets that pharmacy use. BPC-157, TB-500 and the other peptides the FDA's compounding advisory committee reviewed in July 2026 are on neither path today. The committee voted to recommend six of them, but its vote is advice, and as of October 2026 the FDA has not added any of them to the list that would make compounding them lawful[1][5].
What this comes down to
- Two routes make a peptide legal to sell on a prescription: FDA approval, or compounding by a state-licensed pharmacy from a bulk ingredient section 503A allows. Tesamorelin (Egrifta) and bremelanotide (Vyleesi) are approved peptides; so are the GLP-1 drugs.
- In July 2026 an FDA advisory committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, epitalon and Semax for the 503A bulks list. The FDA's own staff had proposed that none of them be added.
- The vote changed nothing yet. Adding a substance takes FDA rulemaking, no rule has been proposed, and none of the six is in the FDA's category 1, the group pharmacies may compound while a decision is pending.
- A peptide labeled for research use only is not a prescription product at all. Before you buy one through a telehealth service, ask which pharmacy fills it and on what legal basis.
- Yes8 yes
- No6 no
- Abstained1 abstention
Vote counts from AJMC's report of the meeting, not from an FDA transcript. The vote is a recommendation, not a decision.
Are peptides legal in the United States?
A peptide is a short chain of amino acids, and the law does not treat peptides as one category. What matters is how a specific one reaches you. The first route is approval: tesamorelin is sold as Egrifta, approved in November 2010 and now held by the FDA as a biologic under BLA 022505, and bremelanotide is sold as Vyleesi under NDA 210557 since June 2019[8][9]. Semaglutide and tirzepatide, the GLP-1 drugs, are peptides with approved products too; the rules for their compounded versions are in compounded tirzepatide in 2026.
The second route is compounding. A pharmacy compounding under section 503A may use a bulk ingredient only if it has a USP or National Formulary monograph, is a component of an FDA-approved drug, or appears on the FDA's 503A bulks list[4]. While the agency works through nominations, it sorts them into categories. It does not intend to act against a pharmacy compounding a category 1 substance; category 2 covers substances with significant safety risks, and for those and category 3 the FDA says it would consider taking action against a compounder[4]. One more limit applies to the largest peptides: biological products are not eligible for the 503A and 503B compounding exemptions at all[7], which is why tesamorelin's status as a biologic matters.
What did the FDA advisory panel vote in July 2026?
On July 23 and 24, 2026, the FDA asked its Pharmacy Compounding Advisory Committee whether seven peptides should be added to the 503A bulks list: BPC-157, KPV, TB-500 and MOTS-c on the first day, emideltide, epitalon and Semax on the second. For each one, in both its free-base and acetate forms, the FDA's own briefing document proposed that it not be included[1].
The committee disagreed for six of the seven. According to trade press, it voted 8 yes, 6 no and 1 abstention to recommend BPC-157, KPV and TB-500 together, 7 to 5 with 2 abstentions for MOTS-c, also recommended epitalon and Semax, and voted emideltide down 7 to 6 with 1 abstention[2]. The pharmacists' trade association reported the same six-and-one split[3]. Those counts come from reporters at the meeting, not from an FDA transcript.
The briefing document says the FDA will not issue a final determination until the committee's input has been considered and all reviews are finalized[1]. The pharmacists' trade association put it plainly: pharmacies will not be permitted to compound the six until final rulemaking is in place[3].
Did the vote make BPC-157 legal?
Not yet. The FDA adds substances to the 503A bulks list through notice-and-comment rulemaking[4], and in early October 2026 the Federal Register carried no proposed rule adding BPC-157 or any of the other five[10]. The FDA's category list, updated May 14, 2026, does not put any of the seven in category 1[5]. All seven sit on the FDA's list of nominations withdrawn from category 2, each with the agency's safety text still printed beside it: for BPC-157, a possible risk of immune reactions for some routes and complexities with peptide-related impurities[6].
The human evidence is thin, which is what the FDA staff weighed. One of the few published human reports on BPC-157 is a 2021 chart review of 16 knee-pain patients at one clinic, contacted by phone, with no comparison group[12]. Our BPC-157 article sets out what has and has not been tested, and the TB-500 evidence does the same for TB-500.
Where does each peptide stand in October 2026?
| Peptide | Approved product | Compounding status today | July 2026 panel |
|---|---|---|---|
| BPC-157 | None | Withdrawn from category 2; not in category 1 or on the 503A list | Recommended, 8 to 6 |
| TB-500 | None | Withdrawn from category 2; not in category 1 or on the 503A list | Recommended, 8 to 6 |
| KPV | None | Withdrawn from category 2; not in category 1 or on the 503A list | Recommended, 8 to 6 |
| MOTS-c | None | Withdrawn from category 2; not in category 1 or on the 503A list | Recommended, 7 to 5 |
| Epitalon | None | Withdrawn from category 2; not in category 1 or on the 503A list | Recommended |
| Semax | None | Withdrawn from category 2; not in category 1 or on the 503A list | Recommended |
| Emideltide (DSIP) | None | Withdrawn from category 2; not in category 1 or on the 503A list | Not recommended, 7 to 6 |
| GHK-Cu | None | Category 1 for non-injectable use only; the FDA plans to consult the committee by February 2027 | Not on the agenda |
| Tesamorelin | Egrifta (a biologic) | Biologics are not eligible for compounding | Not on the agenda |
| Bremelanotide (PT-141) | Vyleesi | A component of an approved drug | Not on the agenda |
Approval from Drugs@FDA. Compounding status from the FDA category list updated May 14, 2026 and the category-2 page dated April 22, 2026. Panel votes as reported by trade press.
The full list of peptides sold online, with trial counts for each, is in every peptide's FDA status.
What does "research use only" mean on a peptide website?
It means the product is not being sold as a drug for people, so no prescriber, pharmacy license or FDA standard stands behind what is in the vial. The FDA has already warned companies that sold GLP-1 drugs falsely labeled for research purposes or not for human consumption while selling them to consumers with dosing instructions, and it urges people not to buy such products because their quality is unknown[11]. A certificate of analysis on a research-peptide site does not change that; what third-party testing proves explains how little one establishes.
How can you tell if a telehealth peptide offer is on the legal route?
- A licensed clinician evaluates you and writes a prescription in your name. A checkout with no prescriber is not a prescription.
- The seller names the pharmacy that fills it and the state that licenses it. How to check a compounding pharmacy walks through the FDA register and the state board lookup.
- Ask the pharmacy what allows it to compound that peptide: an approved-drug component, a monograph, the 503A list or category 1. For BPC-157 and the other five, none of those applies as of October 2026.
- Treat "research use only" or "not for human consumption" as a sign the product is outside the prescription system altogether.
Of the sellers we review, five list at least one of the six peptides the panel backed: Live Vital, Blis MD, YOURx Health, ElitePhysiqMD, and Pepti, and every one of them lists BPC-157. Each review records which pharmacy the company names, when it names one, and these are the questions to put to them before you pay. Sermorelin, which was not part of the July vote, is far more common: 46 sellers we review list it, among them TelePeptide and WePeptideRx.
Questions people actually ask
Is BPC-157 legal?
BPC-157 has no FDA-approved product, it is not on the 503A bulks list, and it is not in the FDA's category 1, so as of October 2026 a pharmacy has no recognized basis to compound it. An FDA advisory committee recommended adding it in July 2026, but that vote is advisory and the FDA has not acted on it.
Is TB-500 legal?
TB-500 is in the same position as BPC-157: no approved product, not on the 503A list, not in category 1, and recommended by the July 2026 advisory committee in the same 8 to 6 vote. Until the FDA finishes rulemaking, the vote does not change its status.
When will the FDA decide on the six peptides?
The FDA has not given a date. Adding a substance to the 503A bulks list takes notice-and-comment rulemaking, and as of early October 2026 no proposed rule for any of the six had appeared in the Federal Register.
Which peptides are FDA-approved?
Tesamorelin (Egrifta) and bremelanotide (Vyleesi) are approved, and so are the peptide GLP-1 drugs such as semaglutide and tirzepatide. The peptides most often sold for recovery or longevity, including BPC-157, TB-500 and MOTS-c, have no approved product.
Is it legal to buy peptides labeled for research use only?
Products labeled for research use only are not sold as drugs for people, and the FDA has warned companies that sold research-labeled GLP-1s to consumers with dosing instructions. The agency urges people not to buy them because their quality is unknown.
Sources
Every source below was read for this article, with the claim it supports written beside it.
- 1.FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026. U.S. Food and Drug Administration, 2026. Source · Document dated July 2026The committee was asked about BPC-157, KPV, TB-500 and MOTS-c (July 23) and emideltide, epitalon and Semax (July 24). For each, in free-base and acetate forms, the FDA proposed that it NOT be included on the 503A bulks list, and said it will not issue a final determination until the committee's input has been considered and all reviews are finalized.
- 2.FDA Panel Backs 6 Peptides for Compounding. AJMC (trade press report of the committee vote), 2026. Source · Document dated July 2026Trade press, not an FDA document: the committee voted 8-6 with 1 abstention to recommend BPC-157, KPV and TB-500, 7-5 with 2 abstentions for MOTS-c, recommended Semax and epitalon, and voted emideltide down 7-6 with 1 abstention.
- 3.FDA advisory committee nominates six peptides for pharmacies to compound. National Community Pharmacists Association (pharmacists' trade association), 2026. Source · Document dated July 2026The committee recommended BPC-157, KPV, TB-500, MOTS-c, epitalon and Semax and rejected emideltide; the votes are not binding, and pharmacies will not be permitted to compound the six until final rulemaking is in place.
- 4.Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. U.S. Food and Drug Administration, 2026. Source · Document dated May 2026A 503A compounder may use a bulk substance only if it has a USP or NF monograph, is a component of an approved drug, or is on the 503A bulks list; the FDA adds substances through notice-and-comment rulemaking and, under its interim policy, does not intend to act on category 1 substances but would consider action for categories 2 and 3.
- 5.Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. U.S. Food and Drug Administration, 2026. Source · Document dated May 2026Updated May 14, 2026: category 1 lists no PCAC peptide; GHK-Cu (except injectable routes) was added back to category 1 and the FDA intends to consult the committee on it before the end of February 2027.
- 6.Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, 2026. Source · Document dated April 2026BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), epitalon and Semax appear among nominations withdrawn from category 2, each with the FDA's safety text; for BPC-157, possible immunogenicity for certain routes and complexities with peptide-related impurities and API characterization.
- 7.Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. Source · Document dated September 2025Biological products are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FD&C Act.
- 8.Drugs@FDA: EGRIFTA (tesamorelin), BLA 022505. U.S. Food and Drug Administration, 2010. Source · Document dated November 2010Tesamorelin is approved as EGRIFTA, now held under a biologics license application, original approval November 10, 2010.
- 9.Drugs@FDA: VYLEESI (bremelanotide), NDA 210557. U.S. Food and Drug Administration, 2019. Source · Document dated June 2019Bremelanotide is approved as VYLEESI, original approval June 21, 2019.
- 10.Federal Register document search: 503A bulk drug substances, July to October 2026. Office of the Federal Register, National Archives, 2026. SourceNo document published from July 1 through October 5, 2026 proposes adding BPC-157 or any other peptide to the 503A bulks list; the same search for the advisory committee's name returned 18 documents in 2026.
- 11.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, 2026. Source · Document dated October 2026The FDA has warned companies that sold unapproved GLP-1 drugs falsely labeled for research purposes or not for human consumption directly to consumers with dosing instructions, and urges consumers not to buy them.
- 12.Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine, 2021. PMID 34324435A retrospective chart review at one clinic: 16 of 17 patients reached by phone, no comparison group, no standardized outcome tools.
Key figures